Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report)’s share price dropped 10.2% on Tuesday . The company traded as low as $17.83 and last traded at $17.87. Approximately 403,603 shares changed hands during trading, an increase of 134% from the average daily volume of 172,190 shares. The stock had previously closed at $19.89.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on TYRA. Oppenheimer raised their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Piper Sandler started coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price on the stock. Wedbush restated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, HC Wainwright increased their price objective on shares of Tyra Biosciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $31.40.
View Our Latest Stock Analysis on TYRA
Tyra Biosciences Stock Performance
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.
Insider Activity at Tyra Biosciences
In other Tyra Biosciences news, CEO Todd Harris sold 19,084 shares of the business’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the sale, the chief executive officer now owns 1,355,927 shares in the company, valued at $37,830,363.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 61,403 shares of company stock worth $1,582,774. 15.40% of the stock is owned by corporate insiders.
Institutional Trading of Tyra Biosciences
Several hedge funds have recently bought and sold shares of TYRA. RA Capital Management L.P. lifted its stake in Tyra Biosciences by 43.9% in the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL lifted its stake in Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares in the last quarter. Perceptive Advisors LLC lifted its stake in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $4,232,000. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $3,047,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
- Five stocks we like better than Tyra Biosciences
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.